Biohaven looking at subgroup data after spinocerebellar ataxia miss

In Biohaven’s first clinical readout since the company accepted Pfizer’s 11-figure takeover offer, a rare disease program destined for a planned spinout has again fallen short of expectations in the clinic.

Biohaven Pharmaceutical Holding Co. Ltd. (NASDAQ:BHVN) said Monday that troriluzole missed the primary endpoint in a Phase III trial to treat spinocerebellar ataxia (SCA), though an efficacy signal seen in a subset of patients may warrant further investigation...